Cyclosporin rapidly diminished a severe lupus-associated macrophage association syndrome refractory to pulsed methylprednisolone and intravenous immunoglobulin.
Takizawa
Y
Y
Maruyama
J
J
Setoguchi
K
K
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage; D007275:Injections, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy* / Q000209:etiology; D008775:Methylprednisolone / Q000008:administration & dosage*
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D016572:Cyclosporine; D008775:Methylprednisolone